229 related articles for article (PubMed ID: 31505052)
1. A CTGF-RUNX2-RANKL Axis in Breast and Prostate Cancer Cells Promotes Tumor Progression in Bone.
Kim B; Kim H; Jung S; Moon A; Noh DY; Lee ZH; Kim HJ; Kim HH
J Bone Miner Res; 2020 Jan; 35(1):155-166. PubMed ID: 31505052
[TBL] [Abstract][Full Text] [Related]
2. Integrin αvβ3 and CD44 pathways in metastatic prostate cancer cells support osteoclastogenesis via a Runx2/Smad 5/receptor activator of NF-κB ligand signaling axis.
Gupta A; Cao W; Chellaiah MA
Mol Cancer; 2012 Sep; 11():66. PubMed ID: 22966907
[TBL] [Abstract][Full Text] [Related]
3. Runx2 association with progression of prostate cancer in patients: mechanisms mediating bone osteolysis and osteoblastic metastatic lesions.
Akech J; Wixted JJ; Bedard K; van der Deen M; Hussain S; Guise TA; van Wijnen AJ; Stein JL; Languino LR; Altieri DC; Pratap J; Keller E; Stein GS; Lian JB
Oncogene; 2010 Feb; 29(6):811-21. PubMed ID: 19915614
[TBL] [Abstract][Full Text] [Related]
4. RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes.
Armstrong AP; Miller RE; Jones JC; Zhang J; Keller ET; Dougall WC
Prostate; 2008 Jan; 68(1):92-104. PubMed ID: 18008334
[TBL] [Abstract][Full Text] [Related]
5. RANKL/RANK/MMP-1 molecular triad contributes to the metastatic phenotype of breast and prostate cancer cells in vitro.
Casimiro S; Mohammad KS; Pires R; Tato-Costa J; Alho I; Teixeira R; Carvalho A; Ribeiro S; Lipton A; Guise TA; Costa L
PLoS One; 2013; 8(5):e63153. PubMed ID: 23696795
[TBL] [Abstract][Full Text] [Related]
6. Gut-derived serotonin induced by depression promotes breast cancer bone metastasis through the RUNX2/PTHrP/RANKL pathway in mice.
Zong JC; Wang X; Zhou X; Wang C; Chen L; Yin LJ; He BC; Deng ZL
Oncol Rep; 2016 Feb; 35(2):739-48. PubMed ID: 26573960
[TBL] [Abstract][Full Text] [Related]
7. Combined therapy with the RANKL inhibitor RANK-Fc and rhApo2L/TRAIL/dulanermin reduces bone lesions and skeletal tumor burden in a model of breast cancer skeletal metastasis.
Holland PM; Miller R; Jones J; Douangpanya H; Piasecki J; Roudier M; Dougall WC
Cancer Biol Ther; 2010 Apr; 9(7):539-50. PubMed ID: 20150760
[TBL] [Abstract][Full Text] [Related]
8. Knockdown of AKT3 Activates HER2 and DDR Kinases in Bone-Seeking Breast Cancer Cells, Promotes Metastasis In Vivo and Attenuates the TGFβ/CTGF Axis.
Hinz N; Baranowsky A; Horn M; Kriegs M; Sibbertsen F; Smit DJ; Clezardin P; Lange T; Schinke T; Jücker M
Cells; 2021 Feb; 10(2):. PubMed ID: 33670586
[TBL] [Abstract][Full Text] [Related]
9. Pathogenic role of connective tissue growth factor (CTGF/CCN2) in osteolytic metastasis of breast cancer.
Shimo T; Kubota S; Yoshioka N; Ibaragi S; Isowa S; Eguchi T; Sasaki A; Takigawa M
J Bone Miner Res; 2006 Jul; 21(7):1045-59. PubMed ID: 16813525
[TBL] [Abstract][Full Text] [Related]
10. Influence of simultaneous targeting of the bone morphogenetic protein pathway and RANK/RANKL axis in osteolytic prostate cancer lesion in bone.
Virk MS; Petrigliano FA; Liu NQ; Chatziioannou AF; Stout D; Kang CO; Dougall WC; Lieberman JR
Bone; 2009 Jan; 44(1):160-7. PubMed ID: 18929692
[TBL] [Abstract][Full Text] [Related]
11. Receptor activator of NF-kappaB ligand enhances breast cancer-induced osteolytic lesions through upregulation of extracellular matrix metalloproteinase inducer/CD147.
Rucci N; Millimaggi D; Mari M; Del Fattore A; Bologna M; Teti A; Angelucci A; Dolo V
Cancer Res; 2010 Aug; 70(15):6150-60. PubMed ID: 20631064
[TBL] [Abstract][Full Text] [Related]
12. IL-11 is essential in promoting osteolysis in breast cancer bone metastasis via RANKL-independent activation of osteoclastogenesis.
Liang M; Ma Q; Ding N; Luo F; Bai Y; Kang F; Gong X; Dong R; Dai J; Dai Q; Dou C; Dong S
Cell Death Dis; 2019 Apr; 10(5):353. PubMed ID: 31040267
[TBL] [Abstract][Full Text] [Related]
13. Targeting of Runx2 by miR-135 and miR-203 Impairs Progression of Breast Cancer and Metastatic Bone Disease.
Taipaleenmäki H; Browne G; Akech J; Zustin J; van Wijnen AJ; Stein JL; Hesse E; Stein GS; Lian JB
Cancer Res; 2015 Apr; 75(7):1433-44. PubMed ID: 25634212
[TBL] [Abstract][Full Text] [Related]
14. DU145 human prostate cancer cells express functional receptor activator of NFkappaB: new insights in the prostate cancer bone metastasis process.
Mori K; Le Goff B; Charrier C; Battaglia S; Heymann D; Rédini F
Bone; 2007 Apr; 40(4):981-90. PubMed ID: 17196895
[TBL] [Abstract][Full Text] [Related]
15. 15-deoxy-δ12,14-prostaglandin j2 inhibits osteolytic breast cancer bone metastasis and estrogen deficiency-induced bone loss.
Kim KR; Kim HJ; Lee SK; Ma GT; Park KK; Chung WY
PLoS One; 2015; 10(4):e0122764. PubMed ID: 25859665
[TBL] [Abstract][Full Text] [Related]
16. Estrogen receptors β1 and β2 have opposing roles in regulating proliferation and bone metastasis genes in the prostate cancer cell line PC3.
Dey P; Jonsson P; Hartman J; Williams C; Ström A; Gustafsson JÅ
Mol Endocrinol; 2012 Dec; 26(12):1991-2003. PubMed ID: 23028063
[TBL] [Abstract][Full Text] [Related]
17. Runx2 induces bone osteolysis by transcriptional suppression of TSSC1.
Wang DC; Wang HF; Yuan ZN
Biochem Biophys Res Commun; 2013 Sep; 438(4):635-9. PubMed ID: 23933319
[TBL] [Abstract][Full Text] [Related]
18. Host-derived RANKL is responsible for osteolysis in a C4-2 human prostate cancer xenograft model of experimental bone metastases.
Morrissey C; Kostenuik PL; Brown LG; Vessella RL; Corey E
BMC Cancer; 2007 Aug; 7():148. PubMed ID: 17683568
[TBL] [Abstract][Full Text] [Related]
19. The role of osteoclastic activity in prostate cancer skeletal metastases.
Keller ET
Drugs Today (Barc); 2002 Feb; 38(2):91-102. PubMed ID: 12532187
[TBL] [Abstract][Full Text] [Related]
20. Runx2 transcriptional activation of Indian Hedgehog and a downstream bone metastatic pathway in breast cancer cells.
Pratap J; Wixted JJ; Gaur T; Zaidi SK; Dobson J; Gokul KD; Hussain S; van Wijnen AJ; Stein JL; Stein GS; Lian JB
Cancer Res; 2008 Oct; 68(19):7795-802. PubMed ID: 18829534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
